The bispecific small molecule ligand EC17 and fluorescein isothiocyanate (FITC) bind folic acid, cause FITC-CAR-T cells to target tumor cells overexpressing FRα, prevent T cell depletion, and improve antigen control flexibility and safety (Lu et al., 2019). Here, FOSL1 is linked to neoplasm.